Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 24 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab for adjuvant treatment of squamous cell carcinoma of the head and neck Atezolizumab (Tecentriq; MPDL3280A) Head and neck cancer Head and Neck Cancer 2021 View  |  Download
Cabozantinib for treating differentiated thyroid cancer Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Differentiated thyroid cancer (DTC) Head and Neck Cancer 2021 View  |  Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Head and neck cancer Head and Neck Cancer 2019 View  |  Download
Durvalumab in combination with Tremelimumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Head and neck cancer Head and Neck Cancer 2018 View  |  Download
Dusquetide for chemoradiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck Dusquetide (SGX942) Chemoradiation-induced oral mucositis Dental and Oral Health , Head and Neck Cancer , Toxicology 2020 View  |  Download
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Head and neck cancer , Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
NBTXR3 (PEP-503) for head and neck squamous cell carcinoma in elderly patients NBTXR3 Head and neck cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab (Opdivo) for Oesophageal Cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Head and neck cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2019 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications